ストックスクリーナーアプリを入手
498.01
0.26%
1.28
プレマーケット:
499.34
1.33
+0.27%
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Vertex Pharmaceuticals (NASDAQ:VRTX) Gains Focus on CASGEVY Expansion - Kalkine Media
Vertex Pharmaceuticals (VRTX) Secures FDA Approval for CASGEVY i - GuruFocus
FDA approves Vertex gene therapy for children as young as 2 By Investing.com - Investing.com Canada
Vertex expands CASGEVY to U.S. children as young as 2 - Stock Titan
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia - Business Wire
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for Pediatric G - GuruFocus
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two - Reuters
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease - GlobeNewswire Inc.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 1 July - Investing.com UK
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 1 July By Investing.com - Investing.com Canada
Joy Liu proposes multiple VRTX share sales (NASDAQ: VRTX) under restricted‑stock vesting - Stock Titan
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals EVP Carmen Bozic sells $287,570 in stock - Investing.com
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Vertex Pharmaceuticals EVP Carmen Bozic sells $287,570 in stock By Investing.com - Investing.com Australia
Vertex (VRTX) CMO sells 596 shares under Rule 10b5-1 trading plan - Stock Titan
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX) - Seeking Alpha
IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Final trades: Vertex Pharma, Verizon, IBM and Corning - MSN
Vertex Pharma guidance and cystic fibrosis focus, shares on NASDAQ in a robust sector setup - AD HOC NEWS
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $615 From $607, Maintains Overweight Rating - Moomoo
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX) - TradingView
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Final Trades: Vertex Pharma, Verizon, IBM and Corning - CNBC
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641 - Moomoo
Vertex Pharma enters Russell 1000 value, shares reflect mixed benchmark shift - AD HOC NEWS
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 3000E Value Benchmark - marketscreener.com
Vertex Pharma analyst optimism builds ahead earnings week, shares trade near recent high - Ad-hoc-news.de
Price to book forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Price to earnings forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharma strategy in cystic fibrosis, shares anchored in the NASDAQ-100 healthcare field - Ad-hoc-news.de
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June - Investing.com UK
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBITDA forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Price to sales forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
VRTX (NASDAQ) affiliate files Form 144: 596 shares vest, multiple sales by Carmen R. Bozic - Stock Titan
Enterprise value to revenue forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:VRTX) - TradingView
Vertex Pharma leads biotech this week, shares hover near record highs - Ad-hoc-news.de
Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles - Fierce Biotech
Vertex Pharmaceuticals Incorporated Actuals & Estimates (BMV:VRTX) - TradingView
Raymond James Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why Vertex Pharmaceuticals (NASDAQ:VRTX) Is Drawing Fresh Attention? - Kalkine Media
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade) (VRTX) - Seeking Alpha
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout | AI
Former Vertex, GSK exec launches science-first pet nutrition company - The Business Journals
Vertex Pharmaceuticals Inc (VRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A Loophole Brings Cystic Fibrosis Patients a ‘Miracle Drug’ in Generic Form - The New York Times
Vertex (VRTX) EVP and CMO Carmen Bozic sells 1,020 shares under 10b5-1 plan - Stock Titan
Vertex Pharma with clear analyst backing, shares supported by strong consensus estimates - Ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable - Yahoo Finance
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance
0.19%
1.97%
大文字化:
|
ボリューム (24 時間):